The programmed death-1 (PD-1) receptor ligands, PD-L1 and PD-L2, are co-stimulatory molecules that contribute to the negative regulation of T lymphocyte activation. It is still unclear whether there is correlation between PD-L1 or PD-L2 and tumour-infiltrating dendritic cells (TIDCs) in cutaneous squamous cell carcinoma (CSCC). The aim of this study was to analyse PD-L1 and PD-L2 expression and dendritic cells infiltration in tumour tissue of CSCC patients and investigate their clinical significance. Immunohistochemical analysis was used to evaluate the expression of PD-L1, PD-L2, CD1a and CD83 in 61 CSCC tissues. The immunofluoresence double-labelling technique was performed to detect the co-expression of PD-L1 or PD-L2 and CD1a or CD83 in tumour tissues. We found that 25 of 61 cases CSCC (40Á98%) exhibited positivity for PD-L1, whereas 37 of 61 cases CSCC (60Á66%) exhibited positivity for PD-L2. A higher percentage of CD1a-positive cases were observed on both PD-L1-positive and PD-L2-positive specimens compared with that of CD83-positive cases (92Á29% versus 37Á60%, 83Á20% versus 33Á16%). The expression of PD-L1 and PD-L2 on CD1a 1 cells was significantly higher than that on CD83 1 cells in tumour tissues of CSCC patients. Furthermore, the expression rate of PD-L1 was associated with UICC stage, and the expression rate of PD-L2 was associated with predominant differentiation and tumour size in CSCC. Our results indicated that higher expression of PD-L1 and PD-L2 on CD1a 1 cells than that on CD83 1 cells in CSCC tumour tissues may contribute to negative regulation in anti-tumour immune responses.
Introduction
Cutaneous squamous cell carcinoma (CSCC) is the second most common type of non-melanoma skin cancer after basal cell carcinoma (BCC), where patients are at higher risk of metastasis and death [1, 2] . Traditional surgical excision is extensive, locally destructive or metastatic; it still poses a therapeutic challenge and treatments are rarely curative [3] . Immunosuppressed patients usually increase their chances to develop CSCC, which arises in previously injured skin such as burn sites, scars, chronic wounds or ulcers, and these tumours typically portend a worse prognosis [4] . This indicates that the immune system may play a pivotal role in the fight against CSCC. Hence, it is critically important to study the immunodepression mechanism in CSCC patients and identify new therapeutic targets for immunotherapy of CSCC. Many researchers have demonstrated that tumour cells could escape immune detection by depleting epidermal dendritic cells (DCs), secreting immunosuppressive factors, a lack of T cell co-stimulation and expression of death ligands or negative ligands, etc. [5] [6] [7] [8] [9] .
Dendritic cells (DCs) are bone marrow (BM)-derived professional antigen-presenting cells that initiate lymphocyte activation and play a pivotal role in the immunobiology of cutaneous lymphoma [10] [11] [12] [13] . Myeloid DCs are differentiated from CD34
1 haematopoietic progenitor cells and can develop into two recognized subsets, Langerhans cells (LCs) and interstitial DCs (IDCs), which are found mainly in the epidermis and connective tissues, respectively [14, 15] . Different series markers, such as CD1a, CD83 and human leucocyte antigen (HLA) class II, can be used to identify DCs [16] . CD83 is a highly specific marker for mature DCs (mDCs), while CD1a often serves as a marker for immature DCs (imDCs) [17] . ImDCs remain immature and sessile within the epidermis and have a relatively low T cell stimulatory ability, while mDCs egress to initiate immune responses. The antigen-presenting ability of DCs can be obstructed by impairing their function through changing the expression of co-stimulatory molecules [18, 19] . Thus, the maturation state of DCs might be one of the important control points for anti-tumour immunotherapy [20] . It is reported that engagement of co-stimulatory molecules such as programmed death ligand 1 (PD-L1) and PD-L2 on antigen-presenting cells (APCs) are involved in the negative regulation of immune responses through inhibition of activated T cells [21] [22] [23] . The up-regulation of PD-L1 in tumours is also correlated inversely with survival of many types of cancer patients [24] [25] [26] [27] [28] . The PD-L1-and PD-L2-related pathways also play a specific role in the suppression of imDCs during the establishment of tolerance [22] . Although inhibition of the PD-1 signal could be effective in the treatment of skin cancers, the underlying mechanism for the PD-1 signal involved in tumour cell escape from immune anti-tumour regulation in CSCC remains unclear. Although many previous studies focus mainly on PD-L1 expression on tumour cells, there are limited pathological data regarding PD-L1 and PD-L2 expression on tumour-infiltrating DCs (TIDCs) and their relationship with the TIDC maturation state, especially in CSCC.
Thus, to our knowledge, the present study explored for the first time the expression of PD-L1 and PD-L2 and their relationship with TIDCs in CSCC patients.
Materials and methods

Patients and controls
Patient consent and ethical approval were obtained prior to the study. The institutional review board of The First Affiliated Hospital of Soochow University approved all protocols. In addition, the study was performed according to the Declaration of Helsinki. The specimens used in this study were obtained from patients who underwent surgical resection for CSCC at The First Affiliated Hospital of Soochow University from January 2010 to March 2014. The control group comprised 15 cases of normal skin tissue from skin biopsy in plastic surgery operations. In all cases, the pathological diagnosis was made by two diagnostic pathologists and two dermatologists, respectively. Staging was performed according to the Union for International Cancer Control (UICC), version 7.0; there were 32 stage I cases, 23 stage II cases, three stage III cases and three stage IV cases. The patients ranged in age from 41 to 84 years, and the mean age was 66Á16 6 17Á38 years. No patient underwent radiation or chemotherapy before surgery. All tumours were evaluated according to haematoxylin and eosin (H&E) staining.
Immunohistochemical staining (IHC) and immunofluorescence
Sections were deparaffinized in xylene for 15 min, and then rehydrated in graded alcohol and water. Endogenous peroxidase activity was blocked by treatment with 3% H 2 O 2 -methanol for 30 min at room temperature (RT). After blocking non-specific binding with serum for 40 min at 378C, sections were incubated with primary monoclonal antibodies directed against PD-L1 [66248-1-immunoglobulin (Ig); Proteintech, Wuhan, China], PD-L2 (MAB1224-500; Bio-techne, Minneapolis, MN, USA), CD1a (ab113618; Abcam, Cambridge, UK) or CD83 (ABIN263553; Antibodies-online.com), respectively, in a humid chamber at 48C overnight. After three washes with phosphate-buffered saline (PBS), sections were incubated with biotinylated secondary antibodies (SA00004-1; Proteintech) for 30 min, washed three times in PBS, and incubated with streptavidin-conjugated peroxidase (ab7403; Abcam) for 30 min. Slides were rinsed in PBS, exposed to diaminobenzidine (SK4100; Vector Laboratories, Burlingame, VA, USA) and counterstained with Mayer's haematoxylin (ab128990; Abcam). The negative controls for these proteins were made by omission of the primary antibody during the process of immunohistochemical staining.
For immunofluorescence, frozen samples were cut into 5-mm-thick serial sections, and after fixing with acetone they were incubated with primary antibodies of PD-L1 or PD-L2, then followed by CD1a (ABIN2037066; Antibodies-online.com) or CD83 (ab205343; Abcam). In a subsequent secondary step, goat anti-rabbit IgG (H 1 L) secondary antibody, Texas Red V R conjugate (T-2767; ThermoFisher Scientific, Fremont, CA, USA) and goat antimouse IgG (H 1 L) secondary antibody, fluorescein isothiocyanate (FITC) conjugate (F-2761; ThermoFisher Scientific) were used. Sections were mounted using Prolong Gold anti-fade mounting medium with 4 0 ,6-diamidino-2-phenylindole [(DAPI) 422801; Biolegend, San Diego, CA, USA]. Images were captured with a fluorescence microscope (BX50; Olympus, Southend-on-Sea, UK) using DP Controller and DP Manager (Olympus) software and a confocal microscope (FV-500; Olympus).
Microscopic evaluation of tumour sections
Diagnoses were verified histologically at the departments of pathology and dermatology, respectively. All the counting was performed in a blinded fashion; the observers were not informed of the outcome of the patients or the results of the other observers. PD-L1, PD-L2 and CD1a proteins were quantified using a visual grading system based on the extent of staining (by percentage of positive tumour cells graded on a scale of 0-3: 0 5 none, 1 5 1-10%, 2 5 11-50%, 3 5 51-100%) and the intensity of staining (graded on a scale of 0-3: 0 5 no staining, 1 5 weak staining, 2 5 moderate staining, 3 5 strong staining). A semiquantitative H-score was obtained by multiplying the grades of extent and intensity of staining. The median value of all the H-scores was chosen as the cut-off value for dividing the expression of proteins into high and low [29] . CD1a-positive DCs were considered to be imLCs, while CD83-positive DCs were considered to be mLCs.
Statistical analysis
The association between immunoreactive markers and clinicopathological variables was analysed statistically using Student's paired t-test, Wilcoxon's rank-sum test, Fisher's exact test or the v 2 test, as appropriate, using Statview software version 4.5 (SAS Institute, Cary, NC, USA). P-values of < 0Á05 were considered statistically significant, and all tests were two-tailed.
Results
PD-L1 and PD-L2 expression in CSCC tissue samples
Among all 61 surgically resected specimens of CSCC without preoperative therapy, the expression of PD-L1 ( Fig. 1 ) and PD-L2 ( Fig. 2) was demonstrated in the cell membrane, cytoplasm or both, respectively. In 61 CSCC cases, the percentage of PD-L1-positive patients was 40Á98% (25 of 61), whereas the percentage of PD-L2-positive patients was 60Á66% (37 of 61). In 61 CSCC cases, the percentage of both PD-L1-and PD-L2-positive patients was 16Á67% (10 of 61). For PD-L1 or Expression of PD-L1 and PD-L2 on CD1a 1 cells was significantly higher than that on CD83 1 cells in CSCC tumour regions
Immunohistochemical studies were used to detect the infiltration of TIDCs in CSCC tumour regions. In this study, CD1a positively stained cells were indicated as imDCs, while CD83 positively stained cells were indicated as mDCs. CD1a-positive specimens were found in 31 (50Á82%) of 61 CSCC samples (Fig. 4) , and CD83 positively stained specimens were detected in 24 (39Á34%) of 61 CSCC cases (Fig. 5) . Similar to PD-L1 and PD-L2 expression, there were also different levels of CD1a or CD83 expression in CSCC tumour regions. In addition, we observed that the percentage of CD1a-positive cases was higher than that of CD83-positive cases on both PD-L1-positive and PD-L2-positive specimens (92Á29 versus 37Á60%, 83Á20 versus 33.16%, Table 1 ). Meanwhile, the percentage of PD-L1-positive and PD-L2-positive cases on CD1a-positive specimens were both higher than that on CD83-positive specimens (74Á42 versus 39Á17%, 99Á31 versus 51Á14%, Table 1 ). For the CD1a and CD83 staining images for all 61 samples, please see Supporting information, Figs S5-S8, respectively. 
To evaluate further whether PD-L1 or PD-L2 expression on CSCC correlated with TIDCs within tumours, we analysed the expression of PD-L1 or PD-L2 and CD1a or CD83 in the same 10 sections (Supporting information, Fig. S9 ) by double immunofluorescence staining. We found that there was CD1a or CD83 co-expression with PD-L1 or PD-L2 in CSCC tumour sections (Figs 6, 7) . Expression of PD-L1 on CD1a 1 cells was significantly higher than that on CD83 1 cells (64Á5 6 10Á29 versus 39Á44 6 11Á18, Fig. 6 , Table 2 ). Similarly, the expression of PD-L2 on CD1a 1 cells was significantly higher than that on CD83 1 cells (73Á91 6 13Á27 versus 48Á44 6 12Á43, Fig. 7 , Table   2 ). In addition, a negative correlation was found between the ratio of CD83/CD1a and PD-L1/CD1a (Fig. 8a) or PD-L2/ CD1a (Fig. 8b) . Our results also revealed a positive correlation between the ratio of PD-L1/CD1a and PD-L1/CD83 (Fig. 8c) , as well as PD-L2/CD1a and PD-L2/CD83 (Fig. 8d) . These results indicated that there was PD-L1 and PD-L2 expression on TIDCs within CSCC tumours, and particularly higher on CD1a 1 cells, which may contribute to negative regulation in anti-tumour immune responses. For the doubleimmunofluorescence staining images for all 10 samples, please refer to Supporting information, Fig. S10 .
The correlation between PD-L1, PD-L2 or CD1a expression and clinicopathological variables of CSCC patients
Finally, we analysed the correlations between PD-L1, PD-L2 or CD1a expression and disease duration, age, gender, tumour site, lymph node metastasis, tumour size, predominant differentiation or UICC stage of CSCC patients by Fisher's exact test, respectively. Table 3 shows the relationships between expression of PD-L1, PD-L2, or CD1a and clinicopathological parameters. Among the 61 CSCC patients with potentially resected tumours, no correlation was observed between PD-L1, PD-L2 or CD1a expression and either disease duration, age, gender, tumour site or lymph node metastasis. Interestingly, correlations of tumour size, predominant differentiation and UICC stage with PD-L1, PD-L2 or CD1a were found (Table 3 ). In multivariate analysis, the percentage of PD-L2-positive CSCC patients was related significantly to tumour size as well as predominant differentiation, and the percentage of PD-L1-positive CSCC cases was related significantly to UICC stage (Table 3) .
Discussion
The immune system in patients with cutaneous squamous cell carcinoma (CSCC) often allows tumours to escape immune surveillance by several strategies [5, 30, 31] . Recent evidence highlights the pivotal role of the T cell co-receptor PD-1 and its ligands PD-L1 and PD-L2 in maintaining an immunosuppressive tumour microenvironment. In addition, it has been reported that PD-L1 blockade improves anti-tumour immunity and represents one approach for cancer immunotherapy [15, 18, 19, 32, 33] . The PD-1-related pathway also plays a specific role in the suppression of imDCs during the establishment of tolerance, as PD-1 and PD-L1/PD-L2 signalling form a co-inhibitory pathway that contributes to the negative regulation of T lymphocyte activation [22, 30] . In this study, we provide evidence of the expression of PD-L1 and PD-L2 in surgically resected specimens of CSCC patients, and there was a statistically sinificant correlation between the percentage of PD-L1 1 patients and UICC stage in CSCC. Moreover, the higher percentage of PD-L2 1 patients in CSCC tissues were related to both tumour size and predominant differentiation. Our results suggest that PD-L1 and PD-L2 may play an important role in disease progression and could be important potential therapeutic targets in CSCC.
In addition, we found that the percentage of CD1a-positive cases were higher on both PD-L1-positive and PD-L2-positive specimens than that of CD83-positive cases. The percentages of both PD-L1 and PD-L2 cases were higher on CD1a-positive specimens than those on CD83-positive specimens. Our results also showed that in the tumour specimens of CSCC, there was a higher percentage of CD1a 1 cases than that of CD83 1 cases (50Á82 versus 39Á34%). The expression of both PD-L1 and PD-L2 on CD1a 1 cells was significantly higher than that on CD83 Table 2 ). A negative correlation between the ratios of CD83/CD1a and PD-L1/CD1a or PD-L2/CD1a was found, and a positive correlation between the ratios of PD-L1/CD1a and PD-L1/CD83 as well as PD-L2/CD1a and PD-L2/CD83 were also observed. These results indicate that TIDCs maturation may correlate negatively with PD-L1 or PD-L2 expression. Thus, we speculated that higher expression of PD-L1 and PD-L2 on CD1a 1 cells than that on CD83 1 cells might play an LCs represent a specific subset of DCs, which are important for detecting and processing pathogens that penetrate the skin and epithelial barriers [18] . ImLCs express high levels of CD1a, langerin (CD207) and Birbeck granules. Upon activation, LCs mature and up-regulate T cell co-stimulatory molecules [major histocompatibility complex (MHC) II, CD40, 80, 83, 86] [31, 34] . In addition, LCs are proposed to have a role in tolerance and the resolution of cutaneous immune responses [35] . PD-L1 and PD-L2 on migratory LCs function to inhibit T cell responses [32] . Thus, these results might also give us another hint that LCs might be a meaningful target to pursue for future immunotherapy in CSCC. Thus, additional studies related to PD-L1 and PD-L2 expression are needed, as well as their receptors, on LCs in CSCC.
We analysed, respectively, the correlation between PD-L1, PD-L2 or CD1a expression and clinicopathological parameters such as age, gender, tumour size, UICC stage, predominant differentiation, etc. using Fisher's exact test in CSCC. We found that the percentage of PD-L1-positvie patients was related to UICC stage. Patients in UICC stages III/IV are a high-risk group with poor prognosis [36] . In addition, PD-L2-positive patients had the high-risk feature of CSCC with tumour size larger than 2 cm. We found that most CSCC are well differentiated, and 73Á4% (28 of 38) PD-L2-positive patients were found to be predominantly differentiated. Therefore PD-L1 or PD-L2 could be used as one of the biomarkers for predicting or diagnosing CSCC. Furthermore, our results showed that the expression of both PD-L1 and PD-L2 was higher on CD1a 1 cells than that on CD83 1 cells in CSCC tumour tissues. These findings suggest that PD-L1 Programmed death-1 ligand 1 and 2 expression in patients with cutaneous squamous cell carcinoma 
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